STOCK TITAN

Moleculin Biotech CEO converts stock units into 577 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Moleculin Biotech, Inc. (MBRX) CEO and President Walter V. Klemp converted 577 restricted stock units into 577 common shares on November 16, 2026. The units convert one-for-one. 141 common shares were withheld for payment of taxes upon vesting, at a reported $7.41 per share. His reported position following the transaction was 126,838 restricted stock units.

Insider KLEMP WALTER V
Role CEO and President
Type Security Shares Price Value
Exercise Restricted Stock Units F1, F3, F4 577 $0.00 $0.00
Exercise Common Stock F1 577 -- --
Tax Withholding Common Stock F2 141 $7.41 $1K
Holdings After Transaction: Restricted Stock Units — 126,838 units (Direct); Common Stock — 36,545 shares (Direct)
Holdings Before and After: Restricted Stock Units, 127,415 to 126,838 units (Direct); Common Stock, 36,109 to 36,545 shares (Direct)
Footnotes (4)
  1. F1. Restricted stock units convert into common stock on a one-for-one basis.
  2. F2. Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
  3. F3. The restricted stock unit set forth in this table vests as follows: (i) 50% on grant; and (ii) 50% in 18 equal installments over 18 months.
  4. F4. Each restricted stock unit represents a contingent right to receive one shares of Company common stock .
Restricted stock units converted 577 restricted stock units Converted on November 16, 2026; units convert into common stock one-for-one
Common shares acquired 577 common shares Received on November 16, 2026, upon conversion of restricted stock units
Shares withheld for taxes 141 common shares Withheld upon vesting on November 16, 2026
Price per withheld share $7.41 per share Reported for the 141 shares withheld for payment of taxes
Restricted stock units following transaction 126,838 restricted stock units Reported position following the November 16, 2026 transaction
Restricted stock units financial
"Restricted stock units convert into common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
one-for-one basis financial
"convert into common stock on a one-for-one basis"
vesting financial
"upon vesting of restricted stock unit awards"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"represents a contingent right to receive one shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Moleculin Biotech CEO Walter V. Klemp receive from RSUs?

He received 577 common shares when 577 restricted stock units converted one-for-one on November 16, 2026.

How many shares were withheld for taxes in Walter V. Klemp’s MBRX filing?

141 common shares were withheld for taxes upon vesting, at $7.41 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KLEMP WALTER V

(Last)(First)(Middle)
C/O MOLECULIN BIOTECH, INC.
5300 MEMORIAL DR., SUITE 950

(Street)
HOUSTON TEXAS 77007

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Moleculin Biotech, Inc. [ MBRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO and President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M577A(1)36,686D
Common Stock11/16/2026F141(2)D$7.4136,545D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)11/16/2026M577 (3) (4)Common Stock577$0126,838D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
3. The restricted stock unit set forth in this table vests as follows: (i) 50% on grant; and (ii) 50% in 18 equal installments over 18 months.
4. Each restricted stock unit represents a contingent right to receive one shares of Company common stock .
/s/ Jonathan P. Foster by Power of Attorney11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading